Chemo may get boost from cholesterol-related drug

Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs.

Besides their deadly consequences, pancreatic cancer and heart disease share a connection with genetic pathways that control cholesterol and a cell signaling system known as the Hedgehog pathway. (The name refers to the shape of its mutated protein in fruit flies, one that resembles the spiky-haired animal.)

Over-activity in the Hedgehog pathway has long been known to trigger many types of cancer and is the focus of five new drugs currently in development. Each of the drugs targets the same cell-surface protein that forms the business end of the Hedgehog pathway, according to the investigators, but tumors find a way to mutate the protein and make cancer cells resistant to these new therapies.

Looking for another way to target the Hedgehog pathway, investigator William Matsui, M.D., Ph.D., professor at the Johns Hopkins Kimmel Cancer Center, teamed up with UCLA biologist Farhad Parhami, Ph.D, who had studied connections between components of cholesterol and Hedgehog pathways.

Parhami found that derivatives of cholesterol, called oxysterols, regulate the Hedgehog pathway via so-called “liver x receptors,” which bind to cholesterol and guide redistribution of cholesterol throughout the body. In doing so, liver x receptors block the Hedgehog pathway.

“Activating liver x receptor could be an alternate target for blocking the Hedgehog pathway,” says Matsui, who notes that activating a target to create an anti-tumor effect is an unusual strategy in therapy. Most drugs currently in development aim to block pathways not activate them, he says.

For the Hopkins study, mice bearing implanted human pancreatic tumors received treatments of a drug called TO901317 that activates liver x receptors along with a chemotherapy drug called gemcitabine. If given alone, the liver-x receptor drug did not affect tumor growth, but in combination with gemcitabine, the tumors shrank, and investigators found a five-fold reduction in expression of Hedgehog pathway components.

Matsui says that pancreatic tumors are crowded with scar tissue, and chemotherapy drugs encounter difficulty finding cancer cells amid the scar tissue. Blocking the Hedgehog pathway by activating liver x receptors may help pancreatic cancer drugs penetrate the tumor and attack cancer cells.

Matsui and Parhami, in collaboration with UCLA chemists Michael Jung and Frank Stappenbeck, are currently developing novel, more effective and safer liver X receptor activators for use in targeting pancreatic cancer and other Hedgehog pathway-mediated tumors.

Funding for the study was provided by the National Cancer Institute.

FOR IMMEDIATE RELEASE SEQUENCING CANCER MUTATIONS: THERE’S AN APP FOR THAT (ABSTRACT # 2095)

Using precise information about an individual’s genetic makeup is becoming increasingly routine for developing tailored treatments for breast, lung, colon and other cancers. But techniques used to identify meaningful gene mutations depend on analyzing sequences of both normal and mutant DNA in tumor samples, a process that can yield ambiguous results. Now, a team of Johns Hopkins researchers says it has developed an easy-to-use online computer software application that can clear up any confusion faster and cheaper than other methods currently used to do the job.

The application, called “Pyromaker,” - and soon a related tutorial - are available free-of-charge at http://pyromaker.pathology.jhmi.edu/. The software generates simulated pyrograms, which are readouts from a gene sequencing technique known as pyrosequencing.

Most pyrograms correspond precisely to a person’s unique mutation or set of mutations, but some mutations can be more difficult to interpret than others, the Johns Hopkins researchers say. “Pyromaker’s value is in rapidly sorting through each of several simulated pyrograms, until there is a clear match with the actual tumor pyrogram,” says James R. Eshleman, M.D., Ph.D., a professor in the departments of pathology and oncology at Johns Hopkins. “Pyromaker enables us to do in minutes, essentially at no cost, what otherwise would take days of further, expensive tests.”

Pyrosequencing works on shorter stretches of DNA than does the traditional method, known as “Sanger,” named for Frederick Sanger who invented the process. But pyrosequencing is also more sensitive in registering the presence of mutant DNA in a tumor sample, which is a mix of tumor and normal cells. That sensitivity makes it very useful for tumor sequencing, says Eshleman, because the mutant genes that drive a tumor’s abnormal growth typically are less prevalent in a tumor sample, compared with normal versions of those genes.

Because a tumor pyrogram is an overlay of both healthy and mutant DNA, identifying the correct sequence may be difficult and further studies to sort it all out can delay diagnosis and add significantly to costs, he says.
###

Contributions to funding for the research came from the Sol Goldman Pancreatic Cancer Research Center, the Michael Rolfe Foundation, the Dick Knox Foundation, and the National Institutes of Health (CA130938).

###

Vanessa Wasta
.(JavaScript must be enabled to view this email address)
410-614-2916
Johns Hopkins Medical Institutions